Adding canagliflozin to current standard of care improves survival, increases quality-adjusted life–years, and reduces treatment costs for people with type 2 diabetes treated in England over a 10-year period, research suggests.
Advisory Board member and Family Physician, Allison Petznick, highlights the impact of rising medication costs on one of her patients, and provides practical suggestions for US physicians to help those struggling to manage the everyday costs of type 2 diabetes.